Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options

Nunes, Mariana; Bartosch, Carla; Abreu, Miguel Henriques; Richardson, Alan; Almeida, Raquel; Ricardo, Sara

Abstract

Ovarian cancer is a highly lethal form of gynecological cancer. This disease often goes undetected until advanced stages, resulting in high morbidity and mortality rates. Unfortunately, many patients experience relapse and succumb to the disease due to the emergence of drug resistance that significantly limits the effectiveness of currently available oncological treatments. Here, we discuss the molecular mechanisms responsible for resistance to carboplatin, paclitaxel, polyadenosine diphosphate ribose polymerase inhibitors, and bevacizumab in ovarian cancer. We present a detailed analysis of the most extensively investigated resistance mechanisms, including drug inactivation, drug target alterations, enhanced drug efflux pumps, increased DNA damage repair capacity, and reduced drug absorption/accumulation. The in-depth understanding of the molecular mechanisms associated with drug resistance is crucial to unveil new biomarkers capable of predicting and monitoring the kinetics during disease progression and discovering new therapeutic targets.

Citation

Nunes, M., Bartosch, C., Abreu, M. H., Richardson, A., Almeida, R., & Ricardo, S. (in press). Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options. Cells, 13(9), Article 786. https://doi.org/10.3390/cells13090786

• Journal Article Type: Review
• Acceptance Date: May 1, 2024
• Online Publication Date: May 4, 2024
• Deposit Date: May 20, 2024
• Journal: Cells
• Publisher: MDPI
• Peer Reviewed: Peer Reviewed
• Volume: 13
• Issue: 9
• Article Number: 786
• DOI: https://doi.org/10.3390/cells13090786
• Public URL: https://keele-repository.worktribe.com/output/829775